2013 a banner year stock prices 40 to 50. Congratulations MRK.

[Anonymous]

Doesn't matter how the numbers add up? Really? The basis for the numbers going up is a farce if the objective is to become a revenue growth company. Why not just fire everybody and sell all the buildings. It puts lots of money in the bank and a tremendous reduction in expenditures.

I'd like to talk to you about a position on my executive team.
Sincerely
KF

 

[Anonymous]

12 to 14 new product launches in 2014.

….and all of them combined may equal one-tenth of losing Zetia/Vytorin. Idiot.

 

[Anonymous]

When the diabetes franchise falters (it's happening now), you'll see the reverse move. The lipid franchise is already as goos as dead. It's a vaccine company now. Accept it. It's a $20 stock, maybe less.

 

[Anonymous]

When the diabetes franchise falters (it's happening now), you'll see the reverse move. The lipid franchise is already as goos as dead. It's a vaccine company now. Accept it. It's a $20 stock, maybe less.

Obviously you are not objective nor educated in finance and creation of future value.

 

[Anonymous]

When the diabetes franchise falters (it's happening now), you'll see the reverse move. The lipid franchise is already as goos as dead. It's a vaccine company now. Accept it. It's a $20 stock, maybe less.

Sorry - but don't hang any hopes on vaccines. Merck's ability to create new vaccines went away last year when we downsized our already meager vaccine basic research group by 50% and then split the remaining 50% among different competing departments. You've got a very few new vaccines in development, but after that the well will quickly run dry.